Trends in deaths from respiratory illness in children in England and Wales from 1968 to 2000

J R Panickar, S R Dodd, R L Smyth, J M Couriel

Background: Childhood mortality has decreased markedly over the last three decades. A study was undertaken to determine trends in deaths from respiratory illness in children in England and Wales.

Methods: Mortality data collected by the Office for National Statistics were analysed. The data included all deaths registered from all causes in children aged between 28 days and 16 years in England and Wales from 1 January 1968 to 31 December 2000. The main outcome measures were overall and age-specific mortality rates due to all respiratory disorders and specific rates for pneumonia, asthma, cystic fibrosis (CF), and bronchiolitis.

Results: In children aged 1–16 years the overall mortality rate (per 100 000 children) declined from 49.9 in 1968 to 16.3 in 2000, and rates due to respiratory illness fell from 8.6 to 1.3. The proportion of all deaths caused by respiratory illness in children aged 28 days to 16 years fell from 30.8% in 1968 to 9.9% in 2000. In post-neonatal infants (aged 28–364 days), the ‘all cause’ mortality rate fell from 592.8 in 1968 to 176 in 2000 and the rates due to respiratory illness fell from 280 to 22.8. In 2000, pneumonia, asthma and CF together accounted for 73% of all respiratory deaths in 1–16 year olds. In this age group, mortality rates per 100 000 for pneumonia fell from 4.22 to 0.57, for asthma from 0.83 to 0.25, and for CF from 0.66 to 0.12 between 1968 and 2000. Over the same period mortality rates for pneumonia in post-neonatal infants fell from 165 to 6.78 per 100 000 and for CF from 4.88 to 0.33. Bronchiolitis mortality rates per 100 000 in post-neonatal infants fell from 21.47 in 1979 to 1.82 in 2000.

Conclusions: Mortality rates due to all respiratory illnesses in children have fallen markedly in the last three decades. This decline has been more rapid than the overall decline in childhood mortality and respiratory diseases are now responsible for a smaller proportion of deaths in children. These data could provide a foundation for assessing the impact on mortality of future health initiatives such as the introduction of a universal pneumococcal vaccination programme in England and Wales.
rates were analysed from 1979 to 2000 as a separate ICD coding for acute bronchiolitis was used from ICD-9. In ICD-8 acute bronchitis and bronchiolitis were coded together (466).

Stata version 8 and SPSS version 11.0 were used for statistical analysis.

RESULTS

The mortality rates from all causes for children aged 1–16 years were 49.9 per 100 000 in 1968, 29.6 in 1985, and 16.3 in 2000. The mortality rates from respiratory illness in this age group were 8.6, 2.6, and 1.3 per 100 000 in 1968, 1985 and 2000, respectively (fig 1). The proportion of deaths due to respiratory causes in children aged 1–16 years fell from 17.3% in 1968 to 8.8% in 1985 and 8.0% in 2000 (fig 1).

By 2000, pneumonia (43%), asthma (20%), and cystic fibrosis (10%) accounted for 73% of the 138 deaths due to respiratory illness in 1–16 year olds.

Far higher mortality rates were seen in post-neonatal infants (age 28–364 days). In this group the overall mortality rates fell from 592.8 in 1968 to 397.6 in 1985 and to 176 in 2000. The mortality rates from respiratory illness in these infants were 280, 65.1, and 22.8 in 1968, 1985 and 2000, respectively. The percentage of deaths due to respiratory causes in this age group fell from 47.2 in 1968 to 16.4 in 1985 and to 13.0 in 2000 (fig 2).

Mortality rates due to childhood pneumonia fell in all age groups (fig 3). The most striking change was in post-neonatal infants where the mortality rate fell from 165 per 100 000 in 1968 to 27 in 1985 and 6.78 in 2000, a fall of 96% in this age group. The absolute numbers of deaths attributed to pneumonia in children aged 28 days to 16 years were 1855 in 1968, 224 in 1985, and 101 in 2000, a fall of 95% over 32 years.

Deaths from cystic fibrosis fell in all age groups since the late 1960s, with the most marked decline in post-neonatal infants (fig 5). The trends in mortality rates were very similar in the 6–10 year and the 11–16 year groups, so these are not shown separately. The rise in mortality rates in 6–16 year olds in the late 1970s and early 1980s was accompanied by a fall in mortality rates in infants and children aged 1–5 years. In
1968, 118 deaths were attributed to cystic fibrosis in children aged 28 days to 16 years compared with 75 in 1985 and 15 in 2000.

Severe acute viral bronchiolitis is seen almost exclusively in infants aged between 1 month and 1 year. The mortality rate due to bronchiolitis in post-neonatal infants fell from 21.47 in 1979 to 1.82 in 2000 (fig 6), and the absolute number of deaths fell from 137 to 11 per annum in the same period.

Mean (SD) male:female mortality rate ratios between 1968 and 2000 were 1.24 (0.17) for pneumonia, 1.41 (0.48) for asthma, and 0.82 (0.28) for cystic fibrosis for children aged 28 days to 16 years, and 1.77 (1.25) for bronchiolitis in post-neonatal infants. There was no significant trend for male:female mortality rate ratios for pneumonia, asthma, cystic fibrosis, or bronchiolitis during the study period.

DISCUSSION

We have shown that, as in all industrialised countries, mortality rates in children have fallen dramatically in England and Wales in the last 32 years. The mortality rates due to respiratory illness have fallen more steeply than the overall rates, and a much smaller proportion of childhood deaths is now due to respiratory disease than in the past. The greatest improvements have been in infants and young children. Between 1968 and 2000, post-neonatal mortality rates from all causes decreased by 70%, while the rates due to respiratory deaths fell by 92%. In 1968 almost half the deaths in post-neonatal infants were attributed to respiratory disease but, by 2000, this proportion had fallen to 13%. In 1–16 year old children mortality rates for total deaths and respiratory deaths fell by 67% and 85%, respectively, between 1968 and 2000, and the percentage of deaths from respiratory disease fell from 17.3 in 1968 to 8.8 in 1985 and to 8.0 in 2000.

There are some limitations to this study. A significant proportion of infants and children who die from pneumonia or bronchiolitis have a serious underlying condition such as congenital anomalies of the cardiorespiratory system or CNS, a chromosomal abnormality, or an immunodeficiency. The ONS does not collect or provide data about these important co-existent conditions which significantly predispose children to death from a respiratory illness. We therefore cannot comment on their contribution to the trends we report. During the period we analysed there were several changes in data collection by the ONS and its predecessors. Between 1984 and 1992 there were changes in the selection of the underlying cause of death from the death certificate. From 1993 automated coding was used to assign the cause of death. It has been suggested that changes in the mortality rates for pneumonia from 1993 may have been influenced by changes in data collection, but it is difficult to quantify these effects accurately. However, our data do not show any sudden alteration in mortality from pneumonia in children at the time of these changes.

Changes in ICD coding can also affect mortality rates for asthma. For example, in 1979, with the introduction of the ninth revision of the ICD (ICD-9), deaths due to asthma with a mention of bronchitis were recorded under asthma unspecified (493.9) rather than bronchitis (490). This change in classification resulted in an apparent increase in the numbers of deaths from asthma, particularly in adults where there may be confusion with other diseases such as chronic obstructive pulmonary disease. Stewart and Nunn reported that the change from ICD-8 to ICD-9 coding caused an apparent 28% increase in asthma mortality in the total population, although in younger age groups the effect was smaller. A survey of deaths from asthma in England showed death certification was more accurate in younger adults than in the elderly. Sears et al showed that in New Zealand the accuracy of certification for asthma deaths was 100% in subjects under 35 years compared with only 50% in patients over 70 years. However, there is little evidence to suggest that changes in diagnostic labelling by clinicians or in ICD coding explains the changes in the mortality rates from asthma for children we describe.

Because pneumonia, asthma, cystic fibrosis, and bronchiolitis together accounted for most of the deaths due to respiratory illness in children aged between 28 days and 16 years in the period studied, we examined these conditions in more detail. Mortality rates due to childhood pneumonia have fallen in all age groups. The rates fell sharply between 1968 and the mid 1980s and have since levelled out. The fall was greatest in post-neonatal infants but, even now, most childhood deaths from pneumonia occur in the first year of life. In 2000, 40% of deaths due to pneumonia in children aged 28 days to 16 years occurred in post-neonatal infants. Our data cannot explain why the number of deaths in children from pneumonia has fallen, but it is probable that improvements in primary, secondary and specialist care, in the use of antimicrobial agents, and in immunisations have all contributed to this reduction. For example, Mulholland et al reported that HiB (Haemophilus influenzae B) conjugate vaccine, which was introduced into the UK in 1992, is 95% effective in preventing invasive HIB disease, 100% effective in preventing HIB pneumonia, and effective in preventing 21% of all radiologically defined pneumonia. The high levels of protection against pertussis and measles provided by immunisation are also likely to have affected mortality. It will be important to study the effect of the proposed programme of pneumococcal vaccination in children on mortality from pneumonia in this population. These data could provide a valuable baseline to assess the impact of new public health clinical measures which may be introduced in the near future. For example, a universal immunisation programme against pneumococcal infection has been shown to be highly

---

**Figure 5** Mortality rates due to cystic fibrosis from 1968 to 2000.

1968, 118 deaths were attributed to cystic fibrosis in children aged 28 days to 16 years compared with 75 in 1985 and 15 in 2000.

Severe acute viral bronchiolitis is seen almost exclusively in infants aged between 1 month and 1 year. The mortality rate due to bronchiolitis in post-neonatal infants fell from 21.47 in 1979 to 1.82 in 2000 (fig 6), and the absolute number of deaths fell from 137 to 11 per annum in the same period.

Mean (SD) male:female mortality rate ratios between 1968 and 2000 were 1.24 (0.17) for pneumonia, 1.41 (0.48) for asthma, and 0.82 (0.28) for cystic fibrosis for children aged 28 days to 16 years, and 1.77 (1.25) for bronchiolitis in post-neonatal infants. There was no significant trend for male:female mortality rate ratios for pneumonia, asthma, cystic fibrosis, or bronchiolitis during the study period.

**Figure 6** Mortality rates (per 100 000) due to bronchiolitis in post-neonatal infants from 1979 to 2000.

Mortality rates due to childhood pneumonia have fallen in all age groups. The rates fell sharply between 1968 and the mid 1980s and have since levelled out. The fall was greatest in post-neonatal infants but, even now, most childhood deaths from pneumonia occur in the first year of life. In 2000, 40% of deaths due to pneumonia in children aged 28 days to 16 years occurred in post-neonatal infants. Our data cannot explain why the number of deaths in children from pneumonia has fallen, but it is probable that improvements in primary, secondary and specialist care, in the use of antimicrobial agents, and in immunisations have all contributed to this reduction. For example, Mulholland et al reported that HiB (Haemophilus influenzae B) conjugate vaccine, which was introduced into the UK in 1992, is 95% effective in preventing invasive HIB disease, 100% effective in preventing HIB pneumonia, and effective in preventing 21% of all radiologically defined pneumonia. The high levels of protection against pertussis and measles provided by immunisation are also likely to have affected mortality. It will be important to study the effect of the proposed programme of pneumococcal vaccination in children on mortality from pneumonia in this population. These data could provide a valuable baseline to assess the impact of new public health clinical measures which may be introduced in the near future. For example, a universal immunisation programme against pneumococcal infection has been shown to be highly
effective in preventing invasive pneumococcal disease, with a reduction in the incidence of radiologically confirmed pneumonia in children of about 25%.19

We found that a decline in asthma mortality rates until the mid 1970s was followed by a rise in the 1980s, a further fall in the early 1990s, and a levelling out since the mid 1990s. This pattern differs somewhat from that in other countries. In the United States, in children aged 0–17 years the asthma mortality rate increased by an average of 3.4% per year from 1980 to 1998.20 In Australia and Germany, asthma related deaths in childhood showed an increase between the mid 1970s and mid 1980s.21 Campbell et al reported an irregular downward trend in 5–14 year olds from 1983 to 1995 in England and Wales with an average fall of about 6% a year.22

The survival of children and adults with cystic fibrosis has improved dramatically in the last 30 years.23 In 1968 there were 118 deaths from cystic fibrosis in children but, by the year 2000, there were only 15. The small increase in deaths in 6–16 year olds in the 1970–1980s occurred when there was a steep fall in post-neonatal mortality rates and mortality rates in 1–5 year olds, which suggests that this reflects survival to a later age. This improved survival is due to multiple factors including earlier diagnosis and more intensive and effective treatment. It is possible that the figures may have been influenced by changes in coding and death certification and more accurate diagnosis. In the past, the recognition of deaths from cystic fibrosis may have been incomplete and mortality rates may have been underestimated. We cannot assess the influence on mortality from cystic fibrosis of factors which can alter the prevalence of the disease such as prenatal diagnosis with therapeutic terminations, or of neonatal screening which became available during the period of our study.

Acute viral bronchiolitis is an important cause of hospital admissions and need for intensive care in infants. Deaths due to bronchiolitis in post-neonatal infants fell by over 92% between 1979 and 2000. During this time there was no change in ICD coding and no evidence of any change in the prevalence of bronchiolitis. It is probable that the reduction in the number of deaths reflects improvements in paediatric care, particularly in paediatric intensive care.

In conclusion, we have observed a marked and progressive fall in deaths in childhood from respiratory disease. This decline has been more rapid than that seen for childhood deaths from all causes, so that today a smaller proportion of childhood deaths are the result of respiratory illness. The most significant decline was in deaths from pneumonia in the first year of life.

ACKNOWLEDGEMENTS

The authors thank Moira Mickelburgh of the Office of National Statistics for providing the data.

Authors’ affiliations

J R Panickar, J M Couriel, Respiratory Unit, Royal Liverpool Children’s Hospital NHS Trust, Alder Hey, Liverpool L12 2AP, UK
SR Dodd, Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool L69 3GS, UK
RL Smyth, Division of Child Health, University of Liverpool, Royal Liverpool Children’s Hospital NHS Trust, Alder Hey, Liverpool L12 2AP, UK

Funding: Respiratory Unit, Royal Liverpool Children’s NHS Trust

Competing interests: none declared.

The work was independent of the funders.

REFERENCES

Trends in deaths from respiratory illness in children in England and Wales from 1968 to 2000

J R Panickar, S R Dodd, R L Smyth and J M Couriel

Thorax 2005 60: 1035-1038 originally published online September 2, 2005
doi: 10.1136/thx.2005.044750

Updated information and services can be found at:
http://thorax.bmj.com/content/60/12/1035

These include:

References
This article cites 15 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/60/12/1035#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Epidemiologic studies (1829)
- Child health (843)
- Asthma (1782)
- Bronchiolitis (112)
- Bronchitis (235)
- TB and other respiratory infections (1273)
- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- Cystic fibrosis (525)
- Drugs: infectious diseases (968)
- Vaccination / immunisation (158)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/